Clinical Trial Insurance Requirements for Sponsors and CROs

Clinical trial insurance is one of the more procedurally specific placements in life sciences. The IRB framework, the IDE risk classification, the sponsor-site agreement structure, and the contractual flow-down of insurance obligations all combine to produce a placement that needs explicit attention to each component. Sponsors who treat the insurance as a checklist item find themselves at trial start with structural gaps. CROs who do not align their own program with sponsor obligations find themselves contractually exposed.

This walks through the regulatory framework that drives clinical trial insurance, the Significant Risk versus Non-Significant Risk distinction that affects coverage requirements, the sponsor-side and CRO-side perspectives, and the structural decisions that affect placements on both sides.

The Regulatory Framework

Three regulations drive clinical trial insurance requirements for FDA-regulated research involving medical devices and drugs.

21 CFR Part 50 governs the protection of human subjects, with Subpart B addressing informed consent requirements. The informed consent document must include a statement describing the extent to which confidentiality of records will be maintained, and a statement about compensation and medical treatment available if injury occurs. The compensation language is the point at which insurance becomes the operational mechanism, even though Part 50 itself does not prescribe specific coverage amounts.

21 CFR Part 56 governs Institutional Review Boards. Subpart C addresses IRB functions and operations. The IRB reviews the protocol, the informed consent document, and the investigator brochure, and IRBs typically require evidence of insurance coverage before approving a trial. The specific insurance requirements vary by IRB, but the categories are predictable: sponsor coverage, investigator coverage, site coverage, and product liability for the investigational article.

21 CFR Part 812 governs Investigational Device Exemptions for medical device clinical investigations. The framework distinguishes Significant Risk (SR) device studies, which require an approved IDE, from Non-Significant Risk (NSR) studies, which operate under abbreviated requirements but still require IRB approval, informed consent, and the substantive Part 50 and Part 56 protections.

For drug studies and biologic studies, parallel frameworks under 21 CFR Part 312 (Investigational New Drug) and other parts apply, with similar insurance considerations though different operational mechanics. For SaMD trials specifically, the protocol may also implicate software-as-medical-device coverage considerations that are not captured in standard CTL wording.

Significant Risk Versus Non-Significant Risk

The SR-NSR distinction is the most consequential classification decision in a device trial. An SR device is one that presents a potential for serious risk to the health, safety, or welfare of subjects, and is intended as an implant, used to support or sustain human life, of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise presents a potential for serious risk. NSR devices are everything else within the device classification, which still includes a range of meaningful clinical risks but at a lower severity profile.

The insurance implications are direct.

For SR studies, the sponsor typically carries clinical trial liability with substantial limits, addresses product liability for the investigational device, and requires sites to maintain their own coverage with the sponsor named as additional insured or with reciprocal coverage language in the clinical trial agreement.

For NSR studies, the structural requirements are similar but the limit calibration is typically lower, and IRBs often accept different sub-limit structures and coverage scope.

The classification is made by the IRB after sponsor presentation, with FDA having override authority. Sponsors who treat NSR as a default underestimate the risk of IRB reclassification, particularly for novel devices, new indications, or pediatric populations. A program structured around NSR limits that has to scale to SR mid-trial creates expensive remediation. For the broader framing on pre-clearance medical device insurance, see What insurance does a medical device company need during FDA clinical trials and 510(k) review?.

Sponsor-Side Coverage

The sponsor of a clinical trial bears the primary financial responsibility for the trial. The coverage stack from the sponsor side includes several distinct lines.

Clinical trial liability (CTL). The dedicated coverage line for clinical trial adverse events. CTL responds to subject injury, the medical treatment owed under the informed consent compensation language, and the legal defense of subject claims arising from the trial. Limits scale with study size, indication risk, patient population, trial duration, and geographic footprint.

Product liability for the investigational article. Even pre-approval, the investigational device or drug carries product liability exposure. The sponsor’s products liability policy needs to specifically address the investigational period, since standard commercial products coverage often excludes investigational use. For a device specifically, the study coverage and the eventual product policy have to be planned together, as a clinical trial reshapes the device insurance program. Federally funded studies add FAR insurance requirements on top, covered in what government contracts require from life sciences companies.

Errors and omissions for sponsor activities. Protocol design errors, monitoring deficiencies, and data integrity issues can give rise to claims where the sponsor’s professional activity is the substantive cause of harm or loss.

Directors and officers. Securities risk from clinical trial communications, forward-looking statements about trial readouts, and material disclosures about study progress run through D&O.

General liability. Standard operational coverage that addresses bodily injury and property damage at sponsor facilities and during sponsor activities.

The structural decisions for sponsors include the coordination between CTL and product liability, the named insured structure when multiple corporate entities participate, the international extension of CTL where trials run across jurisdictions, and the prior-acts and run-off considerations when trials span multiple policy periods. When the trial runs outside the US, the host country sets its own authorization-stage insurance requirements, covered in what insurance a life sciences company needs for a clinical trial outside the US.

CRO-Side Coverage

CROs carry their own coverage requirements that interact with sponsor coverage through the contractual structure of the master services agreement. The CRO’s own program spans more than services, as what insurance a contract research organization needs details.

Errors and omissions for CRO professional services. The core CRO coverage, addressing protocol execution errors, monitoring deficiencies, data management issues, and the substantive professional services the CRO delivers.

General liability with professional services extensions. Operational coverage addressing CRO activity at sponsor or site facilities.

Cyber and data security. CROs handle clinical trial data, often including PHI, and operate under data handling obligations from sponsors that translate into cyber underwriting expectations.

Workers’ compensation and employer’s liability. For CRO employees performing trial-related activities, particularly clinical research associates conducting site monitoring.

The structural decisions for CROs include the coordination with sponsor coverage requirements (reciprocal additional insured language, sub-limit alignment), the international footprint coverage, and the prior-acts considerations for engagements that span multiple policy periods.

The Sponsor-Site Coverage Interaction

The clinical trial site (typically a hospital, academic medical center, or specialized clinical research site) carries its own coverage. The interaction between sponsor coverage and site coverage runs through the clinical trial agreement.

Site coverage typically includes the site’s own general liability and professional liability for the institution and the investigators, and the site’s medical malpractice for clinical care delivered to subjects. The sponsor’s CTL responds to trial-related injury beyond what the site’s coverage addresses, and the CTA allocates responsibility between the parties.

Common structural issues at the sponsor-site interface include inadequate additional insured language, sub-limit mismatches between the sponsor’s CTL and the site’s coverage requirements, named insured errors when the site is part of a health system with multiple legal entities, and effective date misalignment with study initiation.

For investigator-initiated trials, the structure inverts: the investigator becomes the sponsor under the FDA framework, with the corresponding regulatory and insurance obligations. The institutional sponsor relationship and the investigator-as-sponsor relationship produce different coverage structures.

IRB Insurance Requirements

IRBs review the insurance evidence as part of their protocol approval process. Specific IRB requirements vary, but the predictable components include:

Sponsor coverage attestation. Evidence that the sponsor carries adequate clinical trial liability and product liability for the investigational article.

Investigator coverage attestation. Evidence that the principal investigator and sub-investigators are covered through the site’s medical malpractice or equivalent professional coverage.

Site coverage attestation. Evidence that the institution carries coverage for trial-related activities.

Compensation mechanism documentation. The informed consent compensation language needs to map to actual insurance coverage that will respond.

Additional insured and certificate of insurance documentation. Specific to the trial, with appropriate effective dates.

IRBs that find insurance evidence inadequate at protocol review can delay approval, request additional documentation, or condition approval on specific coverage being placed. This is a procedural risk to study start dates and a substantive risk to the trial timeline.

Investigator-Initiated Trials

When the investigator initiates the trial under their own IND or IDE rather than under a corporate sponsor’s framework, the coverage structure inverts. The investigator becomes the sponsor under the FDA regulatory framework and assumes the corresponding regulatory and insurance obligations.

The practical insurance implications include the investigator’s institution typically extending coverage to investigator-initiated activities through specific endorsements, the institution’s professional liability and general liability covering the trial activities with sometimes-elevated sub-limits, and the manufacturer (if any) providing supporting coverage for the product itself without assuming sponsor liability.

Several common structural issues arise. Institutional coverage may carry sub-limits that are inadequate for the trial scope. Coordination between the investigator, the institution, and any manufacturer providing product is often informal and produces gaps at claim. The IRB’s insurance requirements for investigator-initiated trials are sometimes different from sponsor-initiated trials and may not be fully understood by the investigator.

For pharmaceutical companies or device manufacturers supporting investigator-initiated trials, the question is what coverage the manufacturer provides beyond the product itself, what the institution’s coverage looks like, and how the coordination is documented in the supply agreement or collaboration agreement.

Common Sponsor Mistakes

Assuming standard products liability covers investigational use. Commercial products coverage often excludes investigational devices. Pre-clearance product liability needs explicit attention.

Underestimating CTL limit requirements. CTL limits are calibrated to study scope. A multi-site, multi-year, large-population study needs materially different limits than a single-site pilot.

Misclassifying SR-NSR at planning stage. IRBs reclassify. Programs structured around NSR limits that scale to SR mid-trial create expensive remediation.

Missing CRO interaction. CRO coverage requirements in the master services agreement should be specific and verified, not generic.

Skipping international extensions. Global trials require coverage that extends to the trial geography, with attention to the regulatory framework in each jurisdiction.

Common CRO Mistakes

Generic errors and omissions for clinical research services. Generic professional services E&O often lacks the substantive coverage CROs need for protocol design, monitoring, and data management exposures.

Inadequate cyber for clinical data handling. Clinical trial data, often including PHI, requires cyber coverage that addresses the regulatory dimension as well as the breach response dimension.

Sub-limit mismatches with sponsor requirements. A CRO program with strong overall limits but inadequate sub-limits in the specific categories sponsors require produces contractual gaps.

Reciprocal additional insured failures. When CTA language requires reciprocal additional insured arrangements, the actual policy endorsements need to match. Frequent operational gap.

The Placement Complexity

Clinical trial insurance is a specialty placement. The markets writing meaningful CTL limits, the markets writing investigational product liability, and the markets writing CRO professional services are a narrower group than general commercial markets. The placement requires fluency in the IRB framework, the IDE classification, the sponsor-site contractual structure, and the international extensions where applicable.

The pre-binding conversation is substantive. Carriers writing CTL typically ask for the protocol summary, the IDE status, the SR-NSR classification, the projected enrollment, the geographic footprint, the indication, and the patient population before binding. This is not a transactional placement.

A Note on Placement

MedTech Coverage works with sponsors and CROs on clinical trial coverage structured around protocol scope, regulatory framework, geographic footprint, and the contractual structure between sponsor and sites. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets that write clinical trial liability and CRO professional services for the life sciences segment.

If a clinical trial program is being placed for a first trial, restructured for a new indication, or evaluated against a CRO master services agreement, a structured coverage review produces a working document calibrated to the trial’s actual regulatory and operational profile.